What is CUSIP 07725L102?

CUSIP 07725L102 is the security identifier used in SEC filing datasets for ONC - BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share.

Security Snapshot

BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC) Institutional Ownership

Q: Who owns ONC - BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share based on 13F filings?

281 institutions reported positions in ONC - BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share as of Q1 2026. Open the latest holders period and ownership history tables on this page for position-level details.

CUSIP: 07725L102

13F Institutional Holders and Ownership History from Q1 2016 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

281

Shares (Excl. Options)

34,810,506

Price

$296.97

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Ordinary Shares, par value $0.0001 per share
Symbol: ONC on Nasdaq
All holders as of 31 Mar 2026: Q1 2026
Total 13F shares: 34,810,506
Total 13F value: $10,331,636,961
Portfolio coverage rank: 0%
Share change: +932,936
Value change: +$276,647,870
Number of holders: 281
Shares outstanding: 1,448,910,175
SEC-reported price per share: $284.97
Insider filing price: $284.97

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Key facts

ONC - BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share is tracked under CUSIP 07725L102.
281 institutions reported positions in Q1 2026.
2 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 281 to 18 between Q1 2026 and Q2 2026.
SEC-reported value moved from $10,331,636,961 to $7,419,072.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 281 institutions filings for Q1 2026.

Open SEC evidence

Security key

07725L102

Latest holder period

Q1 2026

13F holders

281

13D/G owners

CIK / CUSIP context first

Open Q1 2026 holders ONC full holder history BeOne Medicines Ltd. SEC filings BeOne Medicines Ltd. company facts BeOne Medicines Ltd. insider transactions BeOne Medicines Ltd. 13D/G history

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 07725L102:

Q2 2026 (18 holders) Q1 2026 (281 holders) Q4 2025 (284 holders) Q3 2025 (261 holders) Q2 2025 (240 holders) Q1 2025 (260 holders) Q4 2024 (222 holders) Q3 2024 (221 holders) Q2 2024 (195 holders) Q1 2024 (198 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

ONC

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BAKER BROS. ADVISORS LP	8%	0%	$36,692,201,272	-$1,740,708	115,912,814	-0%	Julian C. Baker	11 Jun 2026
HHLR ADVISORS, LTD.	4.9%	-26%	$16,788,174,431	-$5,939,951,540	68,551,141	-26%	HHLR Advisors, Ltd.	09 May 2025

As of 31 Mar 2026, 281 institutional investors reported holding 34,810,506 shares of BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC). This represents 2.4% of the company’s total 1,448,910,175 outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Latest

Q1 2026

Rows shown

1-25 of 42

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2026 Q2	26,034	$7,419,072	+$1,338,842			$284.97	18
2026 Q1	34,810,506	$10,331,636,961	+$276,647,870	$40,180,041	$30,944,274	$296.97	281
2025 Q4	33,825,761	$10,275,450,364	+$214,065,011	$43,687,878	$33,905,196	$303.81	284
2025 Q3	32,958,063	$11,226,015,297	-$346,958,018	$66,272,675	$50,219,180	$340.70	261
2025 Q2	34,445,503	$8,338,029,358	-$2,097,913,474	$25,659,420	$27,281,289	$242.07	240
2025 Q1	42,522,929	$11,571,304,178	-$300,776,021	$30,918,513	$30,265,305	$272.17	260
2024 Q4	43,668,178	$8,065,581,343	-$576,365,574	$20,410,455	$24,843,495	$184.71	222
2024 Q3	46,519,526	$10,440,141,817	-$116,771,313	$26,649,267	$65,579,301	$224.51	221
2024 Q2	46,804,066	$6,679,478,929	+$49,458,709	$13,282,577	$15,137,187	$142.67	195
2024 Q1	46,433,670	$7,261,664,670	+$228,390,098	$11,306,997	$11,963,835	$156.39	198
2023 Q4	44,965,141	$8,109,589,388	-$358,939,167	$12,264,080	$13,129,808	$180.36	201
2023 Q3	46,934,356	$8,443,617,070	-$8,576,628	$8,921,552	$14,929,210	$179.87	195
2023 Q2	47,044,110	$8,388,424,595	-$134,114,517	$27,747,046	$5,687,770	$178.30	200
2023 Q1	47,729,619	$10,288,729,347	-$365,549,782	$15,628,395	$33,342,491	$215.53	214
2022 Q4	49,411,792	$10,871,665,562	-$822,129,900	$22,148,018	$33,276,922	$219.94	206
2022 Q3	53,491,519	$7,213,600,064	-$18,667,417	$2,764,000	$9,517,000	$134.82	204
2022 Q2	53,542,991	$8,666,746,485	-$222,094,321	$2,218,000	$8,422,320	$161.85	217
2022 Q1	54,923,857	$10,369,831,154	-$143,839,726	$13,713,000	$22,293,000	$188.60	228
2021 Q4	55,475,829	$15,026,076,469	-$242,691,110	$122,053,000	$27,770,000	$270.93	247
2021 Q3	56,111,399	$20,367,209,544	+$187,897,220	$45,048,000	$30,275,000	$363.00	242
2021 Q2	55,478,557	$19,043,602,189	-$143,508,273	$17,296,000	$9,951,000	$343.19	259
2021 Q1	55,905,428	$19,451,416,879	+$655,221,281	$81,416,000	$20,049,000	$348.08	241
2020 Q4	54,296,531	$14,026,755,839	-$183,663,940	$40,050,000	$11,291,000	$258.39	234
2020 Q3	54,822,916	$15,700,067,419	+$1,338,448,467	$7,705,000	$42,794,000	$286.44	238
2020 Q2	50,121,058	$9,441,745,077	+$213,639,854	$2,713,000	$7,253,000	$188.40	209